Another win for Pfizer as RSV vaccine receives FDA special status

US-based Pfizer has already received the FDA’s Breakthrough Therapy Designation for its RSV candidate for pregnant women, and has now been granted the same status in the indication for older patients.


As the battle to be first to the RSV market rages on, Pfizer brings home another win in New York.

The US Food and Drug Administration (FDA) has granted Pfizer its Breakthrough Therapy Designation for the company’s vaccine candidate against respiratory syncytial virus (RSV) for people over 60 years of age.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs